Added daily report
This commit is contained in:
Navan Chauhan
parent
093932992d
commit
0ff22e2ffb
|
|
@ -0,0 +1,215 @@
|
|||
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
||||
<html xmlns="http://www.w3.org/1999/xhtml"><head>
|
||||
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
|
||||
<meta content="text/css" http-equiv="Content-Style-Type"/>
|
||||
<meta content="pandoc" name="generator"/>
|
||||
<title></title>
|
||||
<style type="text/css">code{white-space: pre;}</style>
|
||||
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
|
||||
<body>
|
||||
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
|
||||
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
|
||||
<ul>
|
||||
<li><a href="#from-preprints">From Preprints</a></li>
|
||||
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
|
||||
<li><a href="#from-pubmed">From PubMed</a></li>
|
||||
<li><a href="#from-patent-search">From Patent Search</a></li>
|
||||
</ul>
|
||||
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
|
||||
<ul>
|
||||
<li><strong>Empathy predicts self-isolation behaviour acceptance during coronavirus risk exposure</strong> -
|
||||
<div>
|
||||
Health risk exposure during the global COVID-19 pandemic has required people to adopt self-isolation. Public authorities have therefore had the difficult task of sustaining such protective but stressful behaviour. Evidence shows that besides egoistic drives, the motivation for self-isolation behaviour could be altruistic. However, the type and role of prosocial motivation in the current pandemic is underestimated and its interaction with risk exposure and psychological distress is largely unknown. Here we show that empathic concern for the most vulnerable predicts acceptance of lockdown measures. In two retrospective studies, one with a general population and one with COVID-19 positive patients, we found that 1) along with health risk exposure, empathic concern is a predictor of acceptance of lockdown measures 2) social covariates and psychological distress have no significant impact. Our results support the need to focus on altruistic behaviours while informing the public instead of on fear-inducing messages.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://psyarxiv.com/h9yts/" target="_blank">Empathy predicts self-isolation behaviour acceptance during coronavirus risk exposure</a>
|
||||
</div></li>
|
||||
<li><strong>Recombination and low-diversity confound homoplasy-based methods to detect the effect of SARS-CoV-2 mutations on viral transmissibility</strong> -
|
||||
<div>
|
||||
The SARS-CoV-2 variant carrying the Spike protein mutation G614 was first detected in late January 2020 and within a few months became the dominant form globally. In the months that followed, many studies, both in vitro and in animal models, showed that variants carrying this mutation were more infectious and more readily transmitted than the ancestral Wuhan form. Here we investigate why a recently published study by van Dorp et al. failed to detect such higher transmissibility of the G614 variant using homoplasy-based methods. We show that both low diversity and recombination confound the methods utilized by van Dorp et al. and significantly decrease their sensitivity. Furthermore, though they claim no evidence of recombination in their dataset, we and several other studies identify a subset of the sequences as recombinants, possibly enough to affect their statistic adversely.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.01.29.428535v1" target="_blank">Recombination and low-diversity confound homoplasy-based methods to detect the effect of SARS-CoV-2 mutations on viral transmissibility</a>
|
||||
</div></li>
|
||||
<li><strong>Are we ready for COVID-19's Golden Passport? Insights from a Global Physician Survey</strong> -
|
||||
<div>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
Background: COVID-19 immunity passports could protect the right to free movement but critics worry about insufficient evidence, privacy, fraud, and discrimination. Objective: To characterize the global physician community9s opinions regarding immunity passports. Design: Cross sectional, random stratified sample of physicians registered with Sermo, a global networking platform open to verified and licensed physicians. Main outcome measures: The survey asked: "Digital immunity passports, based on antibody testing, are being considered to offer proof (e.g. via an app or QR code) that a person has developed lasting immunity to COVID-19 and hence can return to work or travel freely. In your opinion, do we know enough about COVID-19 immunity and it9s duration to offer such immunity passports at the present time?" Possible answers were YES, NO, and UNCERTAIN. Results: The survey was completed by 1004 physicians (67 specialties, 40 countries, 49% frontline specialties) with a mean (SD) age of 49.14 (12) years. Overall, 52% answered NO, 17% were UNCERTAIN, and 31% answered YES (p<0.05). EU physicians were more likely to say YES but even among them it did not exceed 35% approval. US physicians (60%) were more likely to say NO (p<0.05) (Figure). Conclusions: Our findings suggest a current lack of support among physicians for immunity passports. It is hoped that ongoing research and vaccine trials will provide further clarity.
|
||||
</p>
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.25.20234195v3" target="_blank">Are we ready for COVID-19's Golden Passport? Insights from a Global Physician Survey</a>
|
||||
</div></li>
|
||||
<li><strong>COVID-19 Prevention via the Science of Habit Formation</strong> -
|
||||
<div>
|
||||
The coronavirus disease 2019 (COVID-19) continues to claim lives worldwide. We propose that the science of habit formation offers strategies to increase adherence to COVID-19 prevention behaviors and has potential to be lifesaving, particularly for high risk groups. Eight elements of habit formation are highlighted: addressing incorrect beliefs, setting goals, devising an action plan, establishing contextual cues, adding reinforcement, engaging in repetition, aiming for automaticity and recognizing that change is difficult. In addition, we offer a set of strategies for forming new habits and eliminating existing habits to contain the spread of COVID-19. These strategies are derived from habit formation principles and behavior change techniques and can inform future treatment development research. With the COVID-19 pandemic still raging, there is currently an urgent opportunity to leap knowledge on habit formation processes and interventions forward.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://psyarxiv.com/57jyg/" target="_blank">COVID-19 Prevention via the Science of Habit Formation</a>
|
||||
</div></li>
|
||||
<li><strong>Robotic RNA extraction for SARS-CoV-2 surveillance using saliva samples</strong> -
|
||||
<div>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
Saliva is an attractive specimen type for asymptomatic surveillance of COVID-19 in large populations due to its ease of collection and its demonstrated utility for detecting RNA from SARS-CoV-2. Multiple saliva-based viral detection protocols use a direct-to-RT-qPCR approach that eliminates nucleic acid extraction but can reduce viral RNA detection sensitivity. To improve test sensitivity while maintaining speed, we developed a robotic nucleic acid extraction method for detecting SARS-CoV-2 RNA in saliva samples with high throughput. Using this assay, the Free Asymptomatic Saliva Testing (IGI-FAST) research study on the UC Berkeley campus conducted 11,971 tests on supervised self-collected saliva samples and identified rare positive specimens containing SARS-CoV-2 RNA during a time of low infection prevalence. In an attempt to increase testing capacity, we further adapted our robotic extraction assay to process pooled saliva samples. We also benchmarked our assay against the gold standard, nasopharyngeal swab specimens. Finally, we designed and validated a RT-qPCR test suitable for saliva self-collection. These results establish a robotic extraction-based procedure for rapid PCR-based saliva testing that is suitable for samples from both symptomatic and asymptomatic individuals.
|
||||
</p>
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.01.10.21249151v2" target="_blank">Robotic RNA extraction for SARS-CoV-2 surveillance using saliva samples</a>
|
||||
</div></li>
|
||||
<li><strong>Modeling effectiveness of testing strategies to prevent COVID-19 in nursing homes--United States, 2020</strong> -
|
||||
<div>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
Background: SARS-CoV-2 outbreaks in nursing homes can be large with high case fatality. Identifying asymptomatic individuals early through serial testing is recommended to control COVID-19 in nursing homes, both in response to an outbreak ("outbreak testing" of residents and healthcare personnel) and in facilities without outbreaks ("non-outbreak testing" of healthcare personnel). The effectiveness of outbreak testing and isolation with or without non-outbreak testing was evaluated. Methods: Using published SARS-CoV-2 transmission parameters, the fraction of SARS-CoV-2 transmissions prevented through serial testing (weekly, every three days, or daily) and isolation of asymptomatic persons compared to symptom-based testing and isolation was evaluated through mathematical modeling using a Reed-Frost model to estimate the percentage of cases prevented (i.e., "effectiveness") through either outbreak testing alone or outbreak plus non-outbreak testing. The potential effect of simultaneous decreases (by 10%) in the effectiveness of isolating infected individuals when instituting testing strategies was also evaluated. Results: Modeling suggests that outbreak testing could prevent 54% (weekly testing with 48-hour test turnaround) to 92% (daily testing with immediate results and 50% relative sensitivity) of SARS-CoV-2 infections. Adding non-outbreak testing could prevent up to an additional 8% of SARS-CoV-2 infections (depending on test frequency and turnaround time). However, added benefits of non-outbreak testing were mostly negated if accompanied by decreases in infection control practice. Conclusions: When combined with high-quality infection control practices, outbreak testing could be an effective approach to preventing COVID-19 in nursing homes, particularly if optimized through increased test frequency and use of tests with rapid turnaround.
|
||||
</p>
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.12.18.20248255v2" target="_blank">Modeling effectiveness of testing strategies to prevent COVID-19 in nursing homes--United States, 2020</a>
|
||||
</div></li>
|
||||
<li><strong>Uncovering clinical risk factors and prediction of severe COVID-19: A machine learning approach based on UK Biobank data</strong> -
|
||||
<div>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
Background: COVID-19 is a major public health concern. Given the extent of the pandemic, it is urgent to identify risk factors associated with disease severity. Accurate prediction of those at risk of developing severe infections is also of high clinical importance. Methods: Based on the UK Biobank(UKBB data), we built machine learning(ML) models to predict the risk of developing severe or fatal infections, and to evaluate major risk factors involved. We first restricted the analysis to infected subjects(N=7846), then performed analysis at a population level, considering those with no known infection as controls(N for controls=465,728). Hospitalization was used as a proxy for severity. Totally 97 clinical variables(collected prior to COVID-19 outbreak) covering demographic variables, comorbidities, blood measurements(e.g. hematological/liver/renal function/metabolic parameters etc.), anthropometric measures and other risk factors (e.g. smoking/drinking habits) were included as predictors. We also constructed a simplified (lite) prediction model using 27 covariates that can be more easily obtained (demographic and comorbidity data). XGboost (gradient boosted trees) was used for prediction and predictive performance was assessed by cross-validation. Variable importance was quantified by Shapley values and accuracy gain. Shapley dependency and interaction plots were used to evaluate the pattern of relationship between risk factors and outcomes. Results: A total of 2386 severe and 477 fatal cases were identified. For the analysis among infected individuals (N=7846),our prediction model achieved AUCs of 0.723(95% CI:0.711-0.736) and 0.814(CI: 0.791-0.838) for severe and fatal infections respectively. The top five contributing factors for severity were age, number of drugs taken(cnt_tx), cystatin C(reflecting renal function), wait-hip ratio (WHR) and Townsend Deprivation index (TDI). For prediction of mortality, the top features were age, testosterone, cnt_tx, waist circumference(WC) and red cell distribution width (RDW). In analyses involving the whole UKBB population, the corresponding AUCs for severity and fatality were 0.696(CI:0.684-0.708) and 0.802(CI:0.778-0.826) respectively. The same top five risk factors were identified for both outcomes, namely age, cnt_tx, WC, WHR and TDI. Apart from the above features, Type 2 diabetes(T2DM), HbA1c and apolipoprotein A were ranked among the top 10 in at least two (out of four) analyses. Age, cystatin C, TDI and cnt_tx were among the top 10 across all four analyses. As for the lite models, the predictive performances in terms of AUC are broadly similar, with estimated AUCs of 0.716, 0.818, 0.696 and 0.811 respectively. The top-ranked variables were similar to above, including for example age, cnt_tx, WC, male and T2DM. Conclusions: We identified a number of baseline clinical risk factors for severe/fatal infection by an ML approach. For example, age, central obesity, impaired renal function, multi-comorbidities and cardiometabolic abnormalities may predispose to poorer outcomes. The presented prediction models may be useful at a population level to help identify those susceptible to developing severe/fatal infections, hence facilitating targeted prevention strategies. Further replications in independent cohorts are required to verify our findings.
|
||||
</p>
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.09.18.20197319v2" target="_blank">Uncovering clinical risk factors and prediction of severe COVID-19: A machine learning approach based on UK Biobank data</a>
|
||||
</div></li>
|
||||
<li><strong>Development of spike receptor-binding domain nanoparticle as a vaccine candidate against SARS-CoV-2 infection in ferrets</strong> -
|
||||
<div>
|
||||
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a causative agent of COVID-19 pandemic, enters host cells via the interaction of its Receptor-Binding Domain (RBD) of Spike protein with host Angiotensin-Converting Enzyme 2 (ACE2). Therefore, RBD is a promising vaccine target to induce protective immunity against SARS-CoV-2 infection. In this study, we report the development of RBD protein-based vaccine candidate against SARS-CoV-2 using self-assembling H. pylori-bullfrog ferritin nanoparticles as an antigen delivery. RBD-ferritin protein purified from mammalian cells efficiently assembled into 24-mer nanoparticles. 16-20 months-old ferrets were vaccinated with RBD-ferritin nanoparticles (RBD-nanoparticles) by intramuscular or intranasal inoculation. All vaccinated ferrets with RBD-nanoparticles produced potent neutralizing antibodies against SARS-CoV-2. Strikingly, vaccinated ferrets demonstrated efficient protection from SARS-CoV-2 challenge, showing no fever, body weight loss and clinical symptoms. Furthermore, vaccinated ferrets showed rapid clearance of infectious viruses in nasal washes and lungs as well as viral RNA in respiratory organs. This study demonstrates the Spike RBD-nanoparticle as an effective protein vaccine candidate against SARS-CoV-2.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.01.28.428743v1" target="_blank">Development of spike receptor-binding domain nanoparticle as a vaccine candidate against SARS-CoV-2 infection in ferrets</a>
|
||||
</div></li>
|
||||
<li><strong>The evolutionary making of SARS-CoV-2</strong> -
|
||||
<div>
|
||||
Covid-19 is the most devastating pandemic of the past 100 years. A zoonotic transfer presumably at a wildlife market introduced the causative virus, SARS-CoV-2 (sarbecovirus; beta-coronavirus), to humans in late 2019. Meanwhile, the mechanistic details of the infection process have been largely elucidated, and structural models explain binding of the virial spike to the human cell surface receptor ACE2. Yet, the evolutionary trajectory that gave rise to this pathogen is poorly understood. Here we scan SARS-CoV-2 protein sequences in-silico for innovations along the evolutionary lineage starting with the last common ancestor of coronaviruses. Substantial differences in the sets of proteins encoded by SARS-CoV-2 and viruses outside sarbecovirus, and in their domain architectures, indicate divergent functional demands. By contrast, sarbecoviruses themselves are almost fully conserved at these levels of resolution. However, profiling spike evolution on the sub-domain level using predicted linear epitopes reveals that this protein was gradually reshaped within sarbecovirus. The only epitope that is private to SARS-CoV-2 overlaps with the furin cleavage site. This lends phylogenetic support to the hypothesis that a change in strategy facilitated the zoonotic transfer of SARS-CoV-2 and its success as a human pathogen. Upon furin cleavage, spike switches from a "stealth mode" where immunodominant ACE2 binding epitopes are largely hidden to an "attack mode" where these epitopes are exposed. The resulting reinforcement of ACE2 binding extends the window of opportunity for cell entry. SARS-CoV-2 variants fine-tuning this mode switch will be particularly threatening as they optimize immune evasion.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.01.29.428808v1" target="_blank">The evolutionary making of SARS-CoV-2</a>
|
||||
</div></li>
|
||||
<li><strong>NUCLEIC TRANSFORMER: DEEP LEARNING ONNUCLEIC ACIDS WITH SELF-ATTENTION ANDCONVOLUTIONS</strong> -
|
||||
<div>
|
||||
Much work has been done to apply machine learning and deep learning to genomics tasks, but these applications usually require extensive domain knowledge and the resulting models provide very limited interpretability. Here we present the Nucleic Transformer, a conceptually simple but effective and interpretable model architecture that excels in a variety of DNA/RNA tasks. The Nucleic Transformer processes nucleic acid sequences with self-attention and convolutions, two deep learning techniques that have proved dominant in the fields of computer vision and natural language processing. We demonstrate that the Nucleic Transformer can be trained in both supervised and unsupervised fashion without much domain knowledge to achieve high performance with limited amounts of data in E. coli promoter classification, viral genome identification, and degradation properties of COVID-19 mRNA vaccine candidates. Additionally, we showcase extraction of promoter motifs from learned attention and how direct visualization of self-attention maps assists informed decision making using deep learning models.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.01.28.428629v1" target="_blank">NUCLEIC TRANSFORMER: DEEP LEARNING ONNUCLEIC ACIDS WITH SELF-ATTENTION ANDCONVOLUTIONS</a>
|
||||
</div></li>
|
||||
<li><strong>Conspiratorial thinking during COVID-19: The roles of paranoia, delusion-proneness, and intolerance of uncertainty</strong> -
|
||||
<div>
|
||||
The COVID-19 global pandemic has left many feeling a sense of profound uncertainty about their world, safety, and livelihood. Information that can help make sense of this uncertainty is offered by both official health-organizations as well as sources espousing misinformation and conspiracy theories. Individuals high in intolerance of uncertainty (IU) may be particularly impacted by the impoverished epistemic environment and may thus be more drawn to conspiratorial thinking (CT). In the present study we show that endorsement of COVID-19-specific conspiracy theories is associated with higher levels of intolerance of uncertainty as well as anxiety, delusion-proneness, and paranoid ideation. Furthermore, delusion-proneness and paranoia explained the relationship between IU and CT, and emerged as independent partial predictors of CT even when controlling for other facets of schizotypy. In contrast, anxiety did not explain the relationship between IU and CT, suggesting a stronger role of cognitive traits as opposed to affective factors. Overall, our findings highlight the importance of individual differences in IU, delusion proneness and paranoia in the development of CT in the context of the acute uncertainty of a global crisis, in which CT is more prevalent and salient. Informational intervention designs may benefit from leveraging the body of work demonstrating the efficacy of targeting IU to incite meaningful changes in thinking.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://psyarxiv.com/mb65f/" target="_blank">Conspiratorial thinking during COVID-19: The roles of paranoia, delusion-proneness, and intolerance of uncertainty</a>
|
||||
</div></li>
|
||||
<li><strong>The SARS-CoV-2 Y453F mink variant displays a striking increase in ACE-2 affinity but does not challenge antibody neutralization</strong> -
|
||||
<div>
|
||||
SARS-CoV-2 transmission from humans to animals has been reported for many domesticated species, including cats, dogs and minks. Identification of novel spike gene mutations appearing in minks has raised major concerns about potential immune evasion and challenges for the global vaccine strategy. The genetic variant, known as cluster-five, arose among farmed minks in Denmark and resulted in a complete shutdown of the worlds largest mink production. However, the functional properties of this new variant are not established. Here we present functional data on the Y453F cluster-five receptor-binding domain (RBD) and show that it does not decrease established humoral immunity or affect the neutralizing response in a vaccine model based on wild-type RBD or spike. However, it binds the human ACE-2 receptor with a four-fold higher affinity suggesting an enhanced transmission capacity and a possible challenge for viral control.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.01.29.428834v1" target="_blank">The SARS-CoV-2 Y453F mink variant displays a striking increase in ACE-2 affinity but does not challenge antibody neutralization</a>
|
||||
</div></li>
|
||||
<li><strong>Heterologous vaccination regimens with self-amplifying RNA and Adenoviral COVID vaccines induce superior immune responses than single dose vaccine regimens in mice</strong> -
|
||||
<div>
|
||||
Several vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet there is limited data on the immune response induced by heterologous vaccination regimens using alternate vaccine modalities. Here, we present a detailed description of the immune response, in mice, following vaccination with a self-amplifying RNA (saRNA) vaccine and an adenoviral vectored vaccine (ChAdOx1 nCoV-19/AZD1222) against SARS-CoV-2. We demonstrate that antibody responses are higher in two dose heterologous vaccination regimens than single dose regimens, with high titre neutralising antibodies induced. Importantly, the cellular immune response after a heterologous regimen is dominated by cytotoxic T cells and Th1+ CD4 T cells which is superior to the response induced in homologous vaccination regimens in mice.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.01.28.428665v1" target="_blank">Heterologous vaccination regimens with self-amplifying RNA and Adenoviral COVID vaccines induce superior immune responses than single dose vaccine regimens in mice</a>
|
||||
</div></li>
|
||||
<li><strong>Development of Parent-Adolescent Relationships During the COVID-19 Pandemic: The Role of Stress and Coping</strong> -
|
||||
<div>
|
||||
The coronavirus disease 2019 (COVID-19) pandemic and the extensive measures to prevent spread of the virus have had a major impact on the daily life of families. Such changes in family routines might have an impact on the quality of parenting and the parent-adolescent relationship. However, not all families might be affected by the crisis to a similar extent. In particular, parents and adolescents who have high levels of COVID-19-related stress might experience reduced quality of parenting or parent-child relationships. Families who are able to cope actively might experience limited or even positive changes in relationships during the COVID-19 pandemic. The current longitudinal, multi-informant, and pre-registered study used data of 240 Dutch parents and adolescents (Mage 11.4 years). Using Latent Change Score models, we examined how parent-reported parenting and adolescent-reported relationship quality changed over a six month’s period, from the pre-COVID-19 to the COVID-19 period. Moreover, we examined the moderating role of parents’ and adolescents’ COVID-19-related stress, coping, and the interaction between stress and coping on relationship change. Results showed that on average both the amount of warmth and conflict in parent-adolescent relationships decreased. For positive parenting, there was a significant interaction effect of stress and coping, with active coping leading to a mitigated decline in the quality of parenting only in families who experienced low levels of COVID-19-related stress.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://psyarxiv.com/urmt9/" target="_blank">Development of Parent-Adolescent Relationships During the COVID-19 Pandemic: The Role of Stress and Coping</a>
|
||||
</div></li>
|
||||
<li><strong>Uniting to Advance Diversity, Equity, and Inclusion in a Pandemic and Post-Pandemic World</strong> -
|
||||
<div>
|
||||
This contribution examines the context for the newly-founded Diversity, Equity, and Inclusion (DEI) Committee of the European Association of Geochemistry. The report summarises the work to advance DEI undertaken during 2020 under conditions of the COVID-19 global pandemic, acknowledges the various impacts for community members, and takes a forward view to opportunities of a post-pandemic world.
|
||||
</div>
|
||||
<div class="article-link article-html-link">
|
||||
🖺 Full Text HTML: <a href="https://osf.io/d6z72/" target="_blank">Uniting to Advance Diversity, Equity, and Inclusion in a Pandemic and Post-Pandemic World</a>
|
||||
</div></li>
|
||||
</ul>
|
||||
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
|
||||
<ul>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: AZD7442; Drug: Placebo<br/><b>Sponsor</b>: AstraZeneca<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Drug: Placebo; Drug: Fluvoxamine<br/><b>Sponsor</b>: SigmaDrugs Research Ltd.<br/><b>Recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Drug: Tocilizumab<br/><b>Sponsor</b>: FMH College of Medicine and Dentistry<br/><b>Completed</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Convalescent Plasma in the Treatment of Covid-19</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Biological: Convalescent plasma from COVID-19 donors; Biological: Placebo<br/><b>Sponsors</b>: Helsinki University Central Hospital; Finnish Red Cross<br/><b>Recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>APT™ T3X on the COVID-19 Contamination Rate</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: Tetracycline hydrochloride 3%; Drug: Placebo<br/><b>Sponsors</b>: University of Nove de Julho; Santa Casa de Misericórdia de Porto Alegre<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy of Nano-Ivermectin Impregnated Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff</strong> - <b>Condition</b>: Covid-19<br/><b>Intervention</b>: Other: ivermectin impregnated mask<br/><b>Sponsor</b>: South Valley University<br/><b>Recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Drug: Ivermectin Tablets; Drug: Doxycycline Tablets; Drug: Placebo<br/><b>Sponsor</b>: Max Health, Subsero Health<br/><b>Recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Immunologic Antiviral Therapy With Omalizumab</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Biological: Omalizumab; Other: Placebo<br/><b>Sponsor</b>: McGill University Health Centre/Research Institute of the McGill University Health Centre<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: Doxycycline Tablets; Drug: Rivaroxaban 15Mg Tab; Combination Product: Hydroxychloroquine and Azithromycin<br/><b>Sponsor</b>: Yaounde Central Hospital<br/><b>Recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase IIb Clinical Trial of Recombinant Novel Coronavirus Pneumonia (COVID-19) Vaccine (Sf9 Cells)</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: Recombinant COVID-19 vaccine (Sf9 cells); Biological: Placebo<br/><b>Sponsors</b>: Jiangsu Province Centers for Disease Control and Prevention; West China Hospital<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19</strong> - <b>Condition</b>: Covid-19<br/><b>Interventions</b>: Drug: Famotidine; Drug: Placebo<br/><b>Sponsors</b>: Northwell Health; Cold Spring Harbor Laboratory<br/><b>Recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 and Pregnancy: Placental and Immunological Impacts</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Other: Specimens specific for the study<br/><b>Sponsor</b>: Hopital Foch<br/><b>Recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Early Use of Hyperimmune Plasma in COVID-19</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Other: hyperimmune plasma<br/><b>Sponsors</b>: Catherine Klersy; Policlinico San Matteo Pavia Fondazione IRCCS<br/><b>Recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Restoration of Endothelial Integrity in Patients With COVID-19 (RELIC)</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Biological: Thawed plasma<br/><b>Sponsor</b>: University of Alabama at Birmingham<br/><b>Not yet recruiting</b></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Drug: GX-I7; Drug: GX-I7 vehicle<br/><b>Sponsor</b>: Genexine, Inc.<br/><b>Recruiting</b></p></li>
|
||||
</ul>
|
||||
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
|
||||
<ul>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification</strong> - CONCLUSION: This work explained the positive characteristics of multi-component, multi-target, and multi-approach intervention with MXSGD in combating COVID-19, and preliminary revealed the antiviral and anti-inflammatory pharmacodynamic substances and mechanism of MXSGD, which might provide insights into the vital role of TCM in the prevention and treatment of COVID-19.</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Cardiovascular protective properties of oxytocin against COVID-19</strong> - SARS-CoV-2 infection or COVID-19 has become a worldwide pandemic; however, effective treatment for COVID-19 remains to be established. Along with acute respiratory distress syndrome (ARDS), new and old cardiovascular injuries are important causes of significant morbidity and mortality in COVID-19. Exploring new approaches managing cardiovascular complications is essential in controlling the disease progression and preventing long-term complications. Oxytocin (OXT), an immune-regulating...</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Selection, Identification, and Characterization of SARS-CoV-2 Monoclonal Antibody Resistant Mutants</strong> - The use of monoclonal neutralizing antibodies (mNAbs) is being actively pursued as a viable intervention for the treatment of Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) infection and associated coronavirus disease 2019 (COVID-19). While highly potent mNAbs have great therapeutic potential, the ability of the virus to mutate and escape recognition and neutralization of mNAbs represents a potential problem in their use for the therapeutic management of SARS-CoV-2. Studies investigating...</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>How IvIg Can Mitigate Covid-19 Disease: A Symmetrical Immune Network Model</strong> - In this report we provide a hypothesis of how intravenous immunoglobulin (IvIg) (pooled therapeutic normal IgG) mitigates the severe disease after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. The disease is caused by an overreaction of the innate immune system producing a cytokine storm and inflicting multiple organ damage. Our interpretation of IvIg therapy hinges on a recent analysis of the immune dysregulation in Covid-19 infection.^((1)) Previous...</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations</strong> - The unprecedented coronavirus SARS-CoV-2 outbreak at Wuhan, China, caused acute respiratory infection to humans. There is no precise vaccine/therapeutic agents available to combat the COVID-19 disease. Some repurposed drugs are saving the life of diseased, but the complete cure is relatively less. Several drug targets have been reported to inhibit the SARS-CoV-2 virus infection, in that TMPRSS2 (transmembrane protease serine 2) is one of the potential targets; inhibiting this protease stops the...</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease</strong> - The two axes of the renin-angiotensin system include the classical ACE/Ang II/AT1 axis and the counter-regulatory ACE2/Ang-(1-7)/Mas1 axis. ACE2 is a multifunctional monocarboxypeptidase responsible for generating Ang-(1-7) from Ang II. ACE2 is important in the vascular system where it is found in arterial and venous endothelial cells and arterial smooth muscle cells in many vascular beds. Among the best characterized functions of ACE2 is its role in regulating vascular tone. ACE2 through its...</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Early Remdesivir Treatment in Covid-19: Why Wait Another Day?</strong> - Antiviral drug efficacy commonly depends on how soon after the onset of the infection is the treatment initiated. For COVID-19 there are no studies available to establish the benefit of early initiation of antivirals on patient outcomes. Remdesivir, an inhibitor of SARS-CoV-2 viral replication, was approved for the treatment of COVID-19 in patients requiring hospitalization. However, studies leading to its approval were conducted in COVID-19 patients with lower respiratory tract infection and/or...</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Degradation of SARS-CoV-2 receptor ACE2 by the E3 ubiquitin ligase Skp2 in lung epithelial cells</strong> - An unexpected observation among the COVID-19 pandemic is that smokers constituted only 1.4%-18.5% of hospitalized adults, calling for an urgent investigation to determine the role of smoking in SARS-CoV-2 infection. Here, we show that cigarette smoke extract (CSE) and carcinogen benzo(a)pyrene (BaP) increase ACE2 mRNA but trigger ACE2 protein catabolism. BaP induces an aryl hydrocarbon receptor (AhR)-dependent upregulation of the ubiquitin E3 ligase Skp2 for ACE2 ubiquitination. ACE2 in lung...</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Mesenchymal Stem Cell-Derived Extracellular Vesicles Carrying miRNA as a Potential Multi Target Therapy to COVID-19: an In Silico Analysis</strong> - In the end of 2019 COVID-19 emerged as a new threat worldwide and this disease present impaired immune system, exacerbated production of inflammatory cytokines, and coagulation disturbs. Mesenchymal stem cell (MSC) derived extracellular vesicles (EVs) have emerged as a therapeutic option due to its intrinsic properties to alleviate inflammatory responses, capable to promote the restoring of injured tissue. EVs contain heterogeneous cargo, including active microRNAs, small noncoding sequences...</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication</strong> - Except remdesivir, no specific antivirals for SARS-CoV-2 infection are currently available. Here, we characterize two small-molecule-compounds, named GRL-1720 and 5h, containing an indoline and indole moiety, respectively, which target the SARS-CoV-2 main protease (M^(pro)). We use VeroE6 cell-based assays with RNA-qPCR, cytopathic assays, and immunocytochemistry and show both compounds to block the infectivity of SARS-CoV-2 with EC(50) values of 15 ± 4 and 4.2 ± 0.7 μM for GRL-1720 and 5h,...</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Anti-inflammatory potential of Quercetin in COVID-19 treatment</strong> - SARS-CoV-2 is a betacoronavirus causing severe inflammatory pneumonia, so that excessive inflammation is considered a risk factor for the disease. According to reports, cytokine storm is strongly responsible for death in such patients. Some of the consequences of severe inflammation and cytokine storms include acute respiratory distress syndrome, acute lung injury, and multiple organ dysfunction syndromes. Phylogenetic findings show more similarity of the SARS-CoV-2 virus with bat coronaviruses,...</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients</strong> - CONCLUSION: These data suggest the potential role of Tα1 in modulating the immune response homeostasis and the cytokine storm in vivo.</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19</strong> - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third coronavirus causing serious human disease to spread across the world in the past 20 years, after SARS and Middle East respiratory syndrome. As of mid-September 2020, more than 200 countries and territories have reported 30 million cases of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, including 950,000 deaths. Supportive treatment remains the mainstay of therapy for COVID-19. The World Health Organization...</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2</strong> - Effective treatment or vaccine is not yet available for combating SARS coronavirus 2 (SARS-CoV-2) that caused the COVID-19 pandemic. Recent studies showed that two drugs, Camostat and Nafamostat, might be repurposed to treat COVID-19 by inhibiting human TMPRSS2 required for proteolytic activation of viral spike (S) glycoprotein. However, their molecular mechanisms of pharmacological action remain unclear. Here, we perform molecular dynamics simulations to investigate their native binding sites...</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium</strong> - The human airway epithelium is the initial site of SARS-CoV-2 infection. We used flow cytometry and single cell RNA-sequencing to understand how the heterogeneity of this diverse cell population contributes to elements of viral tropism and pathogenesis, antiviral immunity, and treatment response to remdesivir. We found that, while a variety of epithelial cell types are susceptible to infection, ciliated cells are the predominant cell target of SARS-CoV-2. The host protease TMPRSS2 was required...</p></li>
|
||||
</ul>
|
||||
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
|
||||
<ul>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>METHOD AND APPARATUS FOR ACQUIRING POWER CONSUMPTION IMPACT BASED ON IMPACT OF COVID-19 EPIDEMIC</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU314745621">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A PHARMACEUTICAL COMPOSITION OF ARTESUNATE AND MEFLOQUINE AND METHOD THEREOF</strong> - A pharmaceutical composition for treating Covid-19 virus comprising a therapeutically effective amount of an artesunate or its pharmaceutically acceptable salts thereof and a mefloquine or its pharmaceutically acceptable salts thereof is disclosed. The pharmaceutical composition comprises the artesunate in the ratio of 0.25% to 66% w/v and mefloquine in the ratio of 0.25% to 90% w/v. The composition is found to be effective for the treatment of COVID -19 (SARS-CoV2). The pharmaceutical composition of Artesunate and Mefloquine has been found to be effective and is unexpectedly well tolerated with a low rate of side-effects, and equally high cure-rates than in comparable treatments. The present invention also discloses a method to preparing the pharmaceutical composition comprising of Artesunate and Mefloquine. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN315303355">link</a></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Zahnbürstenaufsatz, elektrische Versorgungseinheit einer elektrischen Zahnbürste, elektrische Zahnbürste mit einem Zahnbürstenaufsatz, Zahnbürste sowie Testaufsatz für eine elektrische Zahnbürste</strong> -
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Zahnbürstenaufsatz für eine elektrische Zahnbürste (20) umfassend einen Koppelabschnitt (2), über den der Zahnbürstenaufsatz (1) mit einer elektrischen Versorgungseinheit (10) der elektrischen Zahnbürste (20) verbindbar ist und einen Bürstenabschnitt (3), der zur Reinigung der Zähne ausgebildete Reinigungsmittel (3.1) aufweist, dadurch gekennzeichnet, dass an dem Zahnbürstenaufsatz (1) eine Sensoreinheit (4) vorgesehen ist, die dazu ausgebildet ist, selektiv das Vorhandensein eines Virus oder eines Antigen im Speichel eines Nutzers des Zahnbürstenaufsatzes (1) durch Messen zumindest eines virusspezifischen Parameters zu bestimmen.</p></li>
|
||||
</ul>
|
||||
<img alt="embedded image" id="EMI-D00000"/>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
||||
<ul>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE315274678">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 CLASSIFICATION RECOGNITION METHOD BASED ON CT IMAGES OF LUNGS</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU314054415">link</a></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vorrichtung umfassend einen Schutzschirm und einen Filter zum Herausfiltern von Viren aus einem Schall erzeugenden Luftstrom</strong> -
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Vorrichtung (10) umfassend einen Schutzschirm (12) und einen Filter (14) zum Herausfiltern von Viren (16) aus einem Schall erzeugenden Luftstrom (18), der von einem Musiker (20) beim Musizieren mit einem Musikinstrument oder beim Singen erzeugt wird, wobei der Schutzschirm (12) zur Verringerung des Risikos einer Infektion mit den Viren (16) dafür vorgesehen ist, wenigstens einen Teil der mit dem Luftstrom transportierten Viren (16) aufzufangen, der Schutzschirm (12) eine erste Seite (22) und eine zweite Seite (24) aufweist, die voneinander abgewandt sind, und der Schutzschirm (12) wenigstens einen sich von der ersten (22) bis zu der zweiten Seite (24) erstreckenden Durchlass (26) aufweist, wobei dieser Durchlass (26) zum Durchströmen mit wenigstens einem Teil des beim Musizieren erzeugten Luftstroms (18) vorgesehen ist und der Filter (14) zum Herausfiltern von Viren (16) aus dem Luftstrom (18) in dem Durchlass (26) des Schutzschirms (12) angeordnet ist.</p></li>
|
||||
</ul>
|
||||
<img alt="embedded image" id="EMI-D00000"/>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
||||
<ul>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE315274597">link</a></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Seil-Haltevorrichtung</strong> -
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
Seil-Haltevorrichtung (1)</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">mit einem Träger (2), und</li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">mit einer Seil-Klemmeinrichtung (3), die auf dem Träger (2) angeordnet ist.</p></li>
|
||||
</ul>
|
||||
<img alt="embedded image" id="EMI-D00000"/>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
||||
<ul>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE314460193">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A traditional Chinese medicine composition for COVID-19 and/or influenza and preparation method thereof</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU313300659">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Covid 19 - Chewing Gum</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU313269181">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>STOCHASTIC MODEL METHOD TO DETERMINE THE PROBABILITY OF TRANSMISSION OF NOVEL COVID-19</strong> - The present invention is directed to a stochastic model method to assess the risk of spreading the disease and determine the probability of transmission of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN313339294">link</a></p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Fahrzeuglüftungssystem und Verfahren zum Betreiben eines solchen Fahrzeuglüftungssystems</strong> -
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Die Erfindung betrifft ein Fahrzeuglüftungssystem (1) zum Belüften einer Fahrgastzelle (2) eines Fahrzeugs (3), mit einem Umluftpfad (5). Die Erfindung ist gekennzeichnet durch eine wenigstens abschnittsweise in einen Umluftansaugbereich (4) des Umluftpads (5) hineinreichende Sterilisationseinrichtung (6), wobei die Sterilisationseinrichtung (6) dazu eingerichtet ist von einem aus der Fahrgastzelle (2) entnommenen Luftstrom getragene Schadstoffe zu inaktivieren und/oder abzutöten.</p></li>
|
||||
</ul>
|
||||
<img alt="embedded image" id="EMI-D00000"/>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
||||
<ul>
|
||||
<li><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE313868337">link</a></li>
|
||||
</ul>
|
||||
|
||||
|
||||
<script>AOS.init();</script></body></html>
|
||||
|
|
@ -0,0 +1,337 @@
|
|||
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
||||
<html xmlns="http://www.w3.org/1999/xhtml"><head>
|
||||
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
|
||||
<meta content="text/css" http-equiv="Content-Style-Type"/>
|
||||
<meta content="pandoc" name="generator"/>
|
||||
<title></title>
|
||||
<style type="text/css">code{white-space: pre;}</style>
|
||||
<title>Daily-Dose</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><style>*{overflow-x:hidden;}</style><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
|
||||
<body>
|
||||
<h1 data-aos="fade-down" id="daily-dose">Daily-Dose</h1>
|
||||
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
|
||||
<ul>
|
||||
<li><a href="#from-new-yorker">From New Yorker</a></li>
|
||||
<li><a href="#from-vox">From Vox</a></li>
|
||||
<li><a href="#from-the-hindu-sports">From The Hindu: Sports</a></li>
|
||||
<li><a href="#from-the-hindu-national-news">From The Hindu: National News</a></li>
|
||||
<li><a href="#from-bbc-europe">From BBC: Europe</a></li>
|
||||
<li><a href="#from-ars-technica">From Ars Technica</a></li>
|
||||
<li><a href="#from-jokes-subreddit">From Jokes Subreddit</a></li>
|
||||
</ul>
|
||||
<h1 data-aos="fade-right" id="from-new-yorker">From New Yorker</h1>
|
||||
<ul>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Did Biden Just Make Everything Normal Again?</strong> - Reflections on a post-Trump week of refreshingly Presidential behavior and predictably partisan feuding. - <a href="https://www.newyorker.com/news/letter-from-bidens-washington/did-biden-just-make-everything-normal-again">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The GameStop Stock Saga Is Dangerous and All Too Familiar</strong> - As the Federal Reserve surely knows, the longer that speculative bubbles are allowed to inflate, the bigger the eventual bust, and the more negative fallout there is for the economy as a whole. - <a href="https://www.newyorker.com/news/our-columnists/the-gamestop-saga-is-dangerous-and-all-too-familiar">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Did Trump and His Supporters Commit Treason?</strong> - Few events in American history have matched the Framers’ definition as clearly as the insurrection of January 6th. - <a href="https://www.newyorker.com/news/our-columnists/did-donald-trump-and-his-supporters-commit-treason">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>How Black Lives Matter Came to the Academy</strong> - The #BlackInTheIvory hashtag helped to surface decades of bias at universities. - <a href="https://www.newyorker.com/news/the-political-scene/how-black-lives-matter-came-to-the-academy">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Why Rich Countries Should Subsidize Vaccination Around the World</strong> - The economists Selva Demiralp and Muhammed A. Yildirim say there is an economic as well as a moral case for getting COVID-19 vaccines into the arms of the world’s people. - <a href="https://www.newyorker.com/news/q-and-a/why-rich-countries-should-subsidize-vaccination-around-the-world">link</a></p></li>
|
||||
</ul>
|
||||
<h1 data-aos="fade-right" id="from-vox">From Vox</h1>
|
||||
<ul>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The EU-AstraZeneca vaccine fight, explained</strong> -
|
||||
<figure>
|
||||
<img alt="" src="https://cdn.vox-cdn.com/thumbor/0dS7vGe7bfXLtuINl6mcuDahvho=/219x0:3710x2618/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/68743337/GettyImages_1230818393.0.jpg"/>
|
||||
<figcaption>
|
||||
Visitors queue before receiving the AstraZeneca/Oxford Covid-19 vaccine outside a closed department store in Folkestone, UK, on January 27, 2021. | Chris Ratcliffe/Bloomberg via Getty Images
|
||||
</figcaption>
|
||||
</figure></li>
|
||||
</ul>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
The European Union’s vaccination program has struggled, and now the bloc is taking actions that could hamper global vaccine efforts.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="5Zq9bR">
|
||||
A spat between the European Union and the British-Swedish pharmaceutical company AstraZeneca is threatening to hamper global vaccine efforts and raising tensions on the continent as European countries <a href="https://www.nytimes.com/2021/01/27/world/europe/europe-covid-vaccinations.html">struggle to vaccinate</a> their populations <a href="https://www.vox.com/22220301/covid-spread-new-strain-variants-safe-grocery-store-n95-masks-vaccine">amid the threat of new, more virulent strains of the coronavirus.</a>
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="MNwCrF">
|
||||
The EU purchased <a href="https://fortune.com/2021/01/26/astrazeneca-covid-vaccine-dispute-eu-covid19-export-controls/">400 million doses</a> of the AstraZeneca vaccine, which the company made in partnership with Oxford University, in advance of it being approved by EU regulators. But last week, AstraZeneca abruptly <a href="https://www.theguardian.com/world/2021/jan/22/covid-oxfordastrazeneca-vaccine-delivery-to-eu-to-be-cut-by-60">announced</a> that <a href="https://apnews.com/article/europe-coronavirus-pandemic-coronavirus-vaccine-belgium-europe-172b5de3151d923c1b2ac83689599128">due to production issues</a> it would only be able to deliver about 40 percent of the total promised in the first quarter, or <a href="https://www.bbc.com/news/world-europe-55822602">about 31 million doses</a>, to the EU.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="GQQcyJ">
|
||||
That, of course, angered EU leaders, who are desperately trying to inoculate their populations.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="bcGaSW">
|
||||
Reuters <a href="https://www.reuters.com/article/health-coronavirus-eu-astrazeneca/astrazeneca-offers-8-million-extra-doses-to-eu-through-march-source-idUSL1N2K30UO">reported Friday</a> that the company agreed to throw in another 8 million more doses — but the EU says that’s not good enough and is demanding AstraZeneca do more, including utilizing its plants in the United Kingdom to make up the shortfall.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="XDZbd6">
|
||||
AstraZeneca says it can’t do that, and that its contract with the EU (a heavily redacted <a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_21_302">version of which was published Friday</a>) requires only that it make the “best effort” to deliver the vaccines to Europe. The problem is that the EU and AstraZeneca disagree on what “best effort” actually means.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Vu2iqo">
|
||||
And now the fight is threatening to spill over, with alarming implications for the global vaccination effort.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="pKuhGv">
|
||||
On Friday, the European Union <a href="https://twitter.com/EMA_News/status/1355171602531569664?s=20">approved the use of the AstraZeneca vaccine.</a> But it also took the dramatic step of <a href="https://www.bloomberg.com/news/articles/2021-01-28/europe-opens-door-to-vaccine-export-ban-risking-global-backlash">putting export controls on all coronavirus vaccines</a>.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Z62G9r">
|
||||
The final regulation <a href="https://ec.europa.eu/commission/presscorner/detail/en/statement_21_314">is expected to be published Saturday</a>, but it will require vaccine makers to notify the EU when exporting coronavirus vaccines to most countries outside the European Union; more than 90 countries are exempt, but not the United States or the United Kingdom. Individual EU member-states <a href="https://www.politico.eu/article/eu-imposes-export-controls-on-rich-nations-from-saturday/">will then have to authorize those exports</a>, and can block them if <a href="https://www.theguardian.com/world/2021/jan/29/astrazenecas-vaccine-duty-eu-ursula-von-der-leyen">they believe companies exporting the vaccines aren’t making good on their own delivery deals with the EU. </a>
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="SGpz2W">
|
||||
It’s<em> </em>not an outright ban on vaccine exports, and <a href="https://www.cnbc.com/2021/01/29/eu-places-export-controls-on-coronavirus-vaccines.html">they are only expected to last until March</a>, but experts and observers worry it sets a troubling precedent.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="LCXAFB">
|
||||
There are now several vaccines available,<strong> </strong><a href="https://www.vox.com/2021/1/29/22238591/johnson-and-johnson-jnj-vaccine-effective-safety-one-dose-south-africa">and more promising candidates on the way</a>. But the EU-AstraZeneca feud is the latest sign that global cooperation and solidarity on vaccine allocation is failing, said <a href="https://www.globalhealthdelivery.org/about/team/rebecca-weintraub">Rebecca Weintraub, faculty director of the Global Health Delivery Project at Harvard University.<strong> </strong></a>
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="wVNqO1">
|
||||
“This is vaccine nationalism 101,” she said.
|
||||
</p>
|
||||
<h3 id="H5fdXn">
|
||||
The EU was slower to sign a deal with AstraZeneca than the US and UK. That delay may be causing problems now.
|
||||
</h3>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="dwC97Z">
|
||||
The European Union, on behalf of its 27 member-states, made deals with a vaccine makers, betting on a bunch of potential candidates and buying up doses in advance. In total, the EU purchased <a href="https://www.nytimes.com/2021/01/27/world/europe/europe-covid-vaccinations.html">2.3 billion vaccine doses</a> from a handful of companies.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="S50u6z">
|
||||
But, initially, richer EU members like <a href="https://www.reuters.com/article/us-health-coronavirus-germany-vaccine/eu-to-use-2-7-billion-fund-to-buy-promising-covid-19-vaccines-idUSKBN23B0SI">Germany, France, Italy, and the Netherlands</a> began to negotiate deals with vaccine makers themselves, <a href="https://www.reuters.com/article/us-health-coronavirus-eu-vaccines-timeli/how-the-eu-filled-its-basket-in-covid-19-shopping-spree-idUSKBN29B1S3">including with AstraZeneca</a>. “That caused a lot of friction in Europe,” Christian Odendahl, chief economist at the C<a href="https://www.cer.eu/">enter for European Reform</a>, told me. “If you’re integrated both politically and economically, you don’t want to be vaccinated and your neighboring country to not be vaccinated.”
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="5PXuHE">
|
||||
The bloc needed to ensure that smaller, less wealthy member-states without big purchasing power would also be able to get vaccines. The solution? Have the European Union itself take over the vaccine buying process for all of the member-states.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="dr6ol1">
|
||||
“But,” said Paulette Kurzer, an expert on European politics and public health at the University of Arizona, that also turned the whole thing into “a very bureaucratically cumbersome process.” The EU had to consult with the individual governments and balance all their interests. Other issues, <a href="https://www.reuters.com/article/us-health-coronavirus-eu-vaccines/limited-legal-protection-for-covid-vaccine-makers-hampers-eu-deals-idUSKBN25M0RQ">like liability protection</a> and <a href="https://www.washingtonpost.com/world/eu-coronavirus-vaccines-cheaper-than-united-states/2020/12/18/06677e34-4139-11eb-b58b-1623f6267960_story.html">the cost of vaccines</a>, also slowed discussions.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="GBsuek">
|
||||
The European Union did finally strike those deals, with AstraZeneca and other vaccine makers, but it was a later in signing that AstraZeneca contract than others, including the United Kingdom.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="eQ9Noh">
|
||||
Fast forward to December, when the <a href="https://www.vox.com/2020/12/2/21983642/uk-first-approves-pfizer-vaccine-biontech-covid-19">United Kingdom</a> became the first country in the world to authorize a vaccine (the Pfizer-BioNtech one) for emergency use. The US soon followed, but EU approval didn’t <a href="https://www.google.com/search?q=euapproves+pfizer+biontech+vaccine&rlz=1C5CHFA_enUS769US769&oq=euapproves+pfizer+biontech+vaccine&aqs=chrome..69i57j0i22i30.5344j1j7&sourceid=chrome&ie=UTF-8">come toward the end of December.</a>
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ApHe7Y">
|
||||
Already a few weeks behind some of its counterparts, the European Union’s vaccine campaign has stayed sluggish compared to places like <a href="https://www.vox.com/2021/1/14/22215896/israel-vaccine-coronavirus-pfizer-netanyahu">Israel</a> and the United Kingdom.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="ahkfdK">
|
||||
A shortage of doses has meant EU countries have had to scale back <strong>t</strong>he pace of inoculation; <a href="https://www.ft.com/content/fc3825ee-c0bd-4ae8-b1ff-9702192ae02c">Madrid, Spain, for example</a>, is halting its vaccination program this week. Germany’s health minister <a href="https://www.dw.com/en/germany-set-for-10-weeks-of-covid-vaccine-shortage/a-56367295">has said shortages may persist through July.</a>
|
||||
</p>
|
||||
<div id="yErBqq">
|
||||
|
||||
</div>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="GDS4Uq">
|
||||
New doses from AstraZeneca would ease some of this pressure. But then came the bad news, when AstraZeneca <a href="https://www.theguardian.com/world/2021/jan/22/covid-oxfordastrazeneca-vaccine-delivery-to-eu-to-be-cut-by-60">indicated</a> it would fall short of its initial commitment.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="2zI0L4">
|
||||
AstraZeneca CEO Pascal Soriot, in an interview with <a href="https://www.repubblica.it/cronaca/2021/01/26/news/interview_pascal_soriot_ceo_astrazeneca_coronavirus_covid_vaccines-284349628/">Italian newspaper La Repubblica</a>, said that the company was working “24/7” to fix the “glitches” in its European production.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Qf07nC">
|
||||
“But the UK contract was signed three months before the European vaccine deal,” Soriot said. “So with the UK we have had an extra three months to fix all the glitches we experienced. As for Europe, we are three months behind in fixing those glitches.”
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="20nB5U">
|
||||
The EU, though, has insisted that under the terms of the contract, AstraZeneca must <a href="https://abcnews.go.com/Health/wireStory/eu-astrazeneca-publish-heavily-redacted-deal-vaccine-row-75563276">use its manufacturing facilities in Britain</a> to supply the EU with its share of doses. But AstraZeneca <a href="https://abcnews.go.com/Health/wireStory/eu-astrazeneca-publish-heavily-redacted-deal-vaccine-row-75563276">says it must first fulfill its obligations to the United Kingdom</a> before it can supply Europe or anywhere else. Right now, <a href="https://www.independent.co.uk/news/health/covid-vaccine-uk-astrazeneca-b1786684.html">it’s delivering about 2 million doses per week to the UK.</a>
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="k5xD3h">
|
||||
On Friday, AstraZeneca released its purchase agreement with the EU to try to help clear up the confusion. But that didn’t do much to resolve the dispute.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="LqNYHL">
|
||||
European Commissioner Ursula von der Leyen said Friday it’s <a href="https://www.theguardian.com/world/2021/jan/29/astrazenecas-vaccine-duty-eu-ursula-von-der-leyen">“crystal clear”</a> that the contract says AstraZeneca has to use British factories to supply the EU since its EU production is stalled.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="8WtTq5">
|
||||
AstraZeneca, again, is saying that the contract says it has make its “best reasonable effort” to fulfill the dosage orders, and it says that is what it is doing.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="51zI05">
|
||||
So the stalemate between the EU and AstraZeneca remains.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="HxR6G3">
|
||||
In some ways, the details of the contract are beside the point. The European Union — which is facing a lot of pressure from its member-states — is desperate to deliver these vaccines to its citizens. And, <a href="https://www.vox.com/21327487/covid-19-vaccine-coronavirus-trump-us-china-competition">as completely expected</a>, the global demand for a vaccine is vastly outstripping the supply and the pace at which companies can produce them.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="KVhQsr">
|
||||
The European public is frustrated with the vaccine rollout. They see other countries getting vaccinated faster. Individual member-states are in charge of vaccination rollout and distribution in their own borders, so blaming the EU for botching up the procurement process is a good way to deflect some of the blame from their citizens.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="rclPG3">
|
||||
And AstraZeneca — with additional factories located so tantalizingly close in former EU member-state the United Kingdom — is a useful target for the EU to transfer that blame one step further.
|
||||
</p>
|
||||
<h3 id="egxyjD">
|
||||
The EU is using its power to try to get vaccines, at whatever cost. This is the exactly the type of vaccine nationalism the world feared would happen.
|
||||
</h3>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="bstq8n">
|
||||
The EU’s threat to block vaccine exports could directly hurt the UK, <a href="https://www.politico.eu/article/eu-imposes-export-controls-on-rich-nations-from-saturday/">which relies on a plant in Belgium for its Pfizer vaccine doses.</a> But other countries, like Canada, have raised concerns over whether <a href="https://www.startribune.com/the-latest-india-vaccinates-2-million-health-workers/600015116/">their supplies could be affected</a>, too.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="7NcbVE">
|
||||
The biggest fear is that this could be the first domino to fall, as other countries feel they need to act in their own interest, and maybe block exports, or withhold raw materials — whatever leverage they can use to try to muscle vaccine doses for their populations.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="hLGV82">
|
||||
“Our supply chains are global,” <a href="https://www.ise.ncsu.edu/people/jlswann/">Julie Swann</a>, an expert in health systems and supply chains at the North Carolina State University, told me. “While the manufacturing of a supply chain may be in one part of the world, the raw materials or consumables or assembly may be in a different location. This path is potentially dangerous to push as a main strategy.”
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="E3Zjlk">
|
||||
Experts said the world could see a reprise of the early days of the pandemic, when some <a href="https://www.reuters.com/article/us-health-coronavirus-trade-wto/wto-report-says-80-countries-limiting-exports-of-face-masks-other-goods-idUSKCN2253IX">80 countries or customs territories</a> banned or put restrictions on the export of supplies.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="rIDsUr">
|
||||
“This could reignite the “beggar-thy-neighbor” policies that characterized the early days of the pandemic with regard to personal protective equipment, ventilators and other medical supplies,” Thomas J. Bollyky, senior fellow for global health, economics, and development at the Council on Foreign Relations, said.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="7K7OiG">
|
||||
The EU may perceive this decision to be in its self-interest. But if other countries follow suit, it could backfire — on the EU, and the rest of the world. Because it will almost certainly prolong the pandemic.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="NDOvAy">
|
||||
“It’s making more and more clear, the huge chasm between what people are saying and what they’re doing,” <a href="https://globalhealth.duke.edu/people/udayakumar-krishna">Krishna Udayakumar, Director of the Duke Global Health Innovation Center, told me</a>. The EU, in particular, he said, was seen as a leader in global health equity. It’s given a lot of support to Covax, the multilateral effort to help poor countries get vaccinated. And yet, everyone is still looking out for themselves.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="YkD2qv">
|
||||
“At the the end of the day,” he said, the EU is “doing whatever they can to get access to vaccines as quickly for their own population as possible.”
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="CcPC0T">
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="pY1sOS">
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Aj3Nam">
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="6mtVDt">
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Dvc8Ev">
|
||||
</p>
|
||||
<ul>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Norway’s trillion-dollar wealth fund sold the last of its investments in fossil fuel companies</strong> -
|
||||
<figure>
|
||||
<img alt="" src="https://cdn.vox-cdn.com/thumbor/HxfybNoIFlqCnuMi1rR7EuqBhBE=/0x0:3548x2661/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/68742716/GettyImages_142403796.0.jpg"/>
|
||||
<figcaption>
|
||||
The Scarabeo 8 deepwater oil drilling rig stands in a fjord after being refitted at the Westcon AS yard in Olensvag, Norway, on April 3, 2012. | Kristian Helgesen/Bloomberg via Getty Images
|
||||
</figcaption>
|
||||
</figure></li>
|
||||
</ul>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
Norway’s decision was an economic one, but it’s still a step in the right direction on climate change.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="KGnJjH">
|
||||
Norway’s trillion-dollar sovereign wealth fund has sold the last of its portfolio of oil and gas companies in a major step away from the country’s reliance on its petroleum industry.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="zlKqh6">
|
||||
Trond Grande, deputy CEO of the fund, made the announcement of the final sale, which occurred at the end of last year, <a href="https://www.businesslive.co.za/bd/companies/2021-01-29-norway-wealth-fund-withdraws-from-oil-sector/">in a phone call on Thursday</a>.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="JM2Aka">
|
||||
The decision to nix the fund’s portfolio of oil and gas companies, worth $6 billion, was an economic one. In 2020, the fund reported losses of <a href="https://finance.yahoo.com/news/norway-wealth-fund-dumps-oil-050000656.html">$10 billion in oil and gas shares</a> that were worth $40 billion at the start of the year. Back in 2017, the central bank of Norway said the <a href="https://www.nbim.no/en/the-fund/news-list/2017/norges-bank-recommends-the-removal-of-oil-stocks-from-the-benchmark-index-of-the-government-pension-fund-global-gpfg/">government should drop oil and gas investments</a> to protect the wealth fund — the world’s largest — from the price volatility.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Caus2T">
|
||||
It looks as though it is finally acting on that advice. (The fund had a decent year overall, <a href="https://www.theguardian.com/business/2021/jan/28/norways-sovereign-wealth-fund-gains-more-than-90bn-during-2020">earning more than $120 million</a> despite the economic fallout from the coronavirus pandemic.)
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="sz4mOq">
|
||||
Norway’s sovereign wealth fund was created in 1990 to keep the economic benefits of its lucrative oil and gas industry within the country. The fund gains revenue from taxes on Norway’s petroleum industry and from selling leases to private companies looking to extract more oil from its waters.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Af7sSh">
|
||||
With shares in more than <a href="https://www.nbim.no/en/the-fund/about-the-fund/">9,000 companies spanning 74 countries</a> worth an estimated 1.5 percent of total global investments, the wealth fund may be, as US environmentalist Bill McKibben <a href="https://twitter.com/billmckibben/status/1355166209990393861?s=20">tweeted</a>, “earth’s single biggest pool of investment capital.”
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="nLx1Kd">
|
||||
Norway wants to be an international leader on climate change, yet it continues to rely on heavily polluting fossil fuel extraction for continued economic prosperity, a contradiction often referred to as <a href="https://www.vox.com/22227063/norway-oil-gas-climate-change">Norway’s climate change paradox</a>.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="JEflyv">
|
||||
The fact that the fund has pulled out of oil and gas companies is a big step in the right direction. But there’s still a long way to go. That’s because Norway isn’t cutting all ties with its petroleum industry just yet. Not even close.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="Ly2kYl">
|
||||
On January 19, Norway granted 61 licenses for offshore oil exploration to 30 companies. Norwegian Minister of Petroleum and Energy Tina Bru <a href="https://www.regjeringen.no/en/aktuelt/high-interest-in-continued-exploration-activity-on-the-norwegian-continental-shelf/id2829102/">said</a> in an announcement that it is “good news for the Norwegian state as a resource owner.”
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="V5forR">
|
||||
As Bård Lahn, a researcher at Norway’s <a href="https://cicero.oslo.no/en">Center for International Climate Research</a> (CICERO) in Oslo, <a href="https://www.vox.com/22227063/norway-oil-gas-climate-change">told me</a> earlier this month, economic concerns are likely to be the most influential factor pushing Norway away from future oil and gas production.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="N0QBE1">
|
||||
And, sure enough, it appears that rather than addressing environmental concerns, the wealth fund’s decision to sell its portfolio of oil and gas companies was about protecting profits.
|
||||
</p>
|
||||
<ul>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Raven Leilani’s wickedly smart Luster is the Vox Book Club’s February pick</strong> -
|
||||
<figure>
|
||||
<img alt="Luster by Raven Leilani" src="https://cdn.vox-cdn.com/thumbor/DEOrdfjyJHcwg143e02YRMcgrvA=/0x122:310x355/1310x983/cdn.vox-cdn.com/uploads/chorus_image/image/68742335/Luster.0.jpg"/>
|
||||
<figcaption>
|
||||
Farrar, Straus and Giroux
|
||||
</figcaption>
|
||||
</figure></li>
|
||||
</ul>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
Chase away the winter doldrums with the Vox Book Club.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="TG6XTH">
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="b4yZbU">
|
||||
<em>The Vox Book Club is linking to </em><a href="https://go.redirectingat.com/?id=66960X1516588&xs=1&url=https://bookshop.org/shop/voxbookclub&referrer=vox.com&sref=https://www.vox.com/culture/21423100/idiot-elif-batuman-semiotics-language-word-games&xcust=___vx__e_21305989__r_vox.com/vox-book-club__t_w__d" rel="sponsored nofollow noopener" target="_blank"><em><strong>Bookshop.org</strong></em></a><em> to support local and independent booksellers.</em>
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="fhNqox">
|
||||
February is traditionally the month of winter doldrums in much of the US, the month where you might find yourself staring glassy-eyed out the window at dirty slush and wondering whether green grass is a myth. And that seems especially likely to be the case in 2021, as the slow and fraught vaccine rollout continues to creep along apace. So the <a href="https://www.vox.com/vox-book-club">Vox Book Club</a> would like to offer a little bit of brightness to the world with our February book pick, <a href="https://go.redirectingat.com/?id=66960X1516588&xs=1&url=https://bookshop.org/books/luster-9781250809919/9780374194321&referrer=vox.com&sref=https://www.vox.com/culture/22166132/best-books-2020-piranesi-promised-land-vanishing-half-sometimes-you-have-to-lie-mexican-gothic&xcust=___vx__e_21930173__r_google.com__t_w__d_D" rel="sponsored nofollow noopener" target="_blank"><em>Luster</em></a> by Raven Leilani.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="xmigpm">
|
||||
<em>Luster</em> is one of those books that makes the world seem both clearer and more interesting than you thought it was. It concerns 23-year-old Edie, a Black woman living in Brooklyn. After getting fired from her crappy publishing job, Edie moves in with her married white boyfriend, his white wife, and their adopted Black daughter.
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="aMFJUa">
|
||||
Leilani plays out all the psychosexual dynamics of this juicy premise with an eye for surreal dark humor. But what really makes <em>Luster</em> sing is Leilani’s ability to evoke with precise and damning detail the hypocrisy of the smugly virtuous white liberal landscape Edie is trying to navigate. There’s plenty to unpack here, and I’m excited to jump in.
|
||||
</p>
|
||||
<aside id="QWJ15w">
|
||||
<div>
|
||||
|
||||
</div>
|
||||
</aside>
|
||||
<h3 id="m4zBIo">
|
||||
<strong>Here’s the full </strong><a href="https://www.vox.com/2020/4/10/21216559/vox-book-club-join-read-discuss"><strong>Vox Book Club schedule</strong></a><strong> for February 2021</strong>
|
||||
</h3>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="0KiLCN">
|
||||
<strong>Friday, February 12:</strong> Discussion post on <em>Luster </em>published to Vox.com
|
||||
</p>
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom" id="dVc7Yl">
|
||||
<strong>Monday, February 22:</strong> Virtual live event with author Raven Leilani. <a href="https://confirmsubscription.com/h/d/533DCA62F59CA120"><strong>Subscribe to the Vox Book Club newsletter, and we’ll send you an RSVP link as soon as it’s available</strong></a>.
|
||||
</p>
|
||||
<h1 data-aos="fade-right" id="from-the-hindu-sports">From The Hindu: Sports</h1>
|
||||
<ul>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>You won't see all your best players in every series from now on: Jos Buttler on bio-bubble</strong> - The England wicketkeeper supported the ECB's rotation policy during their twin tours of Sri Lanka and India.</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Pujara rises to 6th place in Test rankings, Kohli steady at 4th</strong> - Virat Kohli remained the highest-placed Indian batsman at fourth position even as Cheteshwar Pujara rose a rung to sixth in the latest ICC Test rank</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ganguly likely to be discharged from hospital if test results return normal</strong> - “Ganguly’s health condition is stable. He slept well on Friday night and had light food in the morning,” an official said</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Langer’s coaching style not liked by players, coach defends himself: Australian media report</strong> - Australia head coach Justin Langer’s intense “micro-management” coaching style has apparently not gone down well with a lot of players even as the fo</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>No Ranji Trophy for first time in 87 years</strong> - BCCI to hold Hazare Trophy as per State units’ wish</p></li>
|
||||
</ul>
|
||||
<h1 data-aos="fade-right" id="from-the-hindu-national-news">From The Hindu: National News</h1>
|
||||
<ul>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vijith has Maoist links: NIA</strong> - He had ties with Jaleel who was killed in an encounter</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Three more fully reserved daily specials</strong> - The Railway Board has approved the introduction of three more fully reserved daily express special trains.The trains are 07235 KSR Bengaluru-Nagercoil</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>AIMIM MP tweets video of two men waving guns on Mumbai-Pune Expressway, calls them ‘Shiv Sainiks’</strong> - The Shiv Sena said the police would carry out a probe into the incident and take necessary steps as everyone was equal before the law.</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>India proposes law to ban cryptocurrencies, create official digital currency</strong> - The law will "create a facilitative framework for creation of the official digital currency to be issued by the Reserve Bank of India"</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Not surprised at 'evil attack' as we were on higher alert for few weeks: Israeli envoy</strong> - Israeli authorities are providing all assistance and every information to the Indian authorities probing the attack, says Ron Malka</p></li>
|
||||
</ul>
|
||||
<h1 data-aos="fade-right" id="from-bbc-europe">From BBC: Europe</h1>
|
||||
<ul>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Coronavirus: WHO criticises EU over vaccine export controls</strong> - "Vaccine nationalism" risks causing a "protracted recovery", the organisation's chief warns.</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Covid: EU approves AstraZeneca vaccine amid supply row</strong> - The EU approves AstraZeneca's Covid vaccine, but accuses the firm of breaking supply commitments.</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Covid-19: France closes borders to most non-EU travel</strong> - Only essential travel from outside the bloc will be allowed from Sunday, but a lockdown is resisted.</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Poland abortion ban: Thousands protest for third day</strong> - Thousands march through the streets of Warsaw, chanting "freedom, equality, abortion on demand".</p></li>
|
||||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Austrian man leaves 'large amount' to village that saved family from Nazis</strong> - A 90-year-old Austrian man leaves a gift to Le Chambon-sur-Lignon in France for saving his family.</p></li>
|
||||
</ul>
|
||||
<h1 data-aos="fade-right" id="from-ars-technica">From Ars Technica</h1>
|
||||
<ul>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Lawmakers take aim at insidious digital “dark patterns”</strong> - New laws bar efforts to trick consumers into handing over data or money. - <a href="https://arstechnica.com/?p=1738389">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>9 Russian adventurers mysteriously froze to death—a new theory explains why</strong> - 60 years later, new evidence points to a peculiar kind of avalanche as the culprit. - <a href="https://arstechnica.com/?p=1738364">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>What’s really going on with Elon Musk, the FAA, and Starship?</strong> - In the end, it's likely that cooler heads will prevail. - <a href="https://arstechnica.com/?p=1738310">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>It’s the wombat’s strange intestines, not its anus, that produces cubed poo</strong> - "Our research finally proves that you really can fit a square peg through a round hole." - <a href="https://arstechnica.com/?p=1738028">link</a></p></li>
|
||||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Cable ISP warns “excessive” uploaders, says network can’t handle heavy usage</strong> - Mediacom says heavy uploaders harm network even if they don't exceed data cap. - <a href="https://arstechnica.com/?p=1738315">link</a></p></li>
|
||||
</ul>
|
||||
<h1 data-aos="fade-right" id="from-jokes-subreddit">From Jokes Subreddit</h1>
|
||||
<ul>
|
||||
<li><strong>What did the lesbian vampire say to her girlfriend?</strong> - <!-- SC_OFF -->
|
||||
<div class="md">
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
"Same time next month?"
|
||||
</p>
|
||||
</div>
|
||||
<!-- SC_ON -->
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/wimpykidfan37"> /u/wimpykidfan37 </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/l83jk0/what_did_the_lesbian_vampire_say_to_her_girlfriend/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/l83jk0/what_did_the_lesbian_vampire_say_to_her_girlfriend/">[comments]</a></span></p></li>
|
||||
<li><strong>I called up GameStop customer support</strong> - <!-- SC_OFF -->
|
||||
<div class="md">
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
They told me to hold.
|
||||
</p>
|
||||
</div>
|
||||
<!-- SC_ON -->
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/TintinDaSaila"> /u/TintinDaSaila </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/l89ubl/i_called_up_gamestop_customer_support/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/l89ubl/i_called_up_gamestop_customer_support/">[comments]</a></span></p></li>
|
||||
<li><strong>TIL in germany when someone is diagnosed with coeliac disease other coeliacs will chase and try and hit them with bread to make them feel welcomed.</strong> - <!-- SC_OFF -->
|
||||
<div class="md">
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
It's called gluten tag.
|
||||
</p>
|
||||
</div>
|
||||
<!-- SC_ON -->
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/boatsandcurrents"> /u/boatsandcurrents </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/l8ifcm/til_in_germany_when_someone_is_diagnosed_with/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/l8ifcm/til_in_germany_when_someone_is_diagnosed_with/">[comments]</a></span></p></li>
|
||||
<li><strong>To the guy in the wheelchair that stole my camouflage jacket,</strong> - <!-- SC_OFF -->
|
||||
<div class="md">
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
You can hide, But you can’t run.
|
||||
</p>
|
||||
</div>
|
||||
<!-- SC_ON -->
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/ScaryFeet_"> /u/ScaryFeet_ </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/l8hba7/to_the_guy_in_the_wheelchair_that_stole_my/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/l8hba7/to_the_guy_in_the_wheelchair_that_stole_my/">[comments]</a></span></p></li>
|
||||
<li><strong>I called the tinnitus hotline</strong> - <!-- SC_OFF -->
|
||||
<div class="md">
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||||
but it just kept ringing :/
|
||||
</p>
|
||||
</div>
|
||||
<!-- SC_ON -->
|
||||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"> submitted by <a href="https://www.reddit.com/user/harsshvvardhan"> /u/harsshvvardhan </a> <br/> <span><a href="https://www.reddit.com/r/Jokes/comments/l7xx53/i_called_the_tinnitus_hotline/">[link]</a></span> <span><a href="https://www.reddit.com/r/Jokes/comments/l7xx53/i_called_the_tinnitus_hotline/">[comments]</a></span></p></li>
|
||||
</ul>
|
||||
|
||||
|
||||
<script>AOS.init();</script></body></html>
|
||||
File diff suppressed because one or more lines are too long
Loading…
Reference in New Issue